Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glial cell line-derived neurotrophic factor receptor alpha 1 (GFRα1) is a glycosylphosphatidylinositol (GPI)-anchored cell surface co-receptor for glial cell line-derived neurotrophic factor (GDNF), mainly expressed in neurons of the central and peripheral nervous system. Upon GDNF binding, GFRα1 interacts with and activates the transmembrane RET receptor tyrosine kinase, forming a high-affinity signaling complex essential for neuronal survival, maintenance, and differentiation. GFRα1, together with RET and GDNF, mediates signal transduction through MAPK and PI3K pathways, promoting neurotrophic and developmental effects. Dysregulation of the GDNF/GFRα1/RET pathway is implicated in several neurological diseases, cancers, and developmental disorders, making GFRα1 a therapeutically relevant target for modulating neuroprotection and regeneration.
Ligand-induced activation: GDNF binds GFRα1, which recruits and activates the RET tyrosine kinase receptor, initiating downstream signaling (MAPK, PI3K/AKT). GFRα1 agonists mimic GDNF, triggering neurotrophic signaling through RET activation.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glial cell line-derived neurotrophic factor receptor alpha 1 (GFRα1).